Table 3.
Any amount of PT (n=10,005) |
PT ≥45 min on ≥3 d (n=3,277) |
PT ≥150 min on ≥5 d (n=349) |
||||
---|---|---|---|---|---|---|
Characteristic | No. (%) | OR (95% CI) | No. (%) | OR (95% CI) | No. (%) | OR (95% CI) |
Sex | ||||||
Female (Ref.) | 6,115 (10.7) | 1.00 | 1,303 (4.2) | 1.00 | 114 (0.4 (114) | 1.00 |
Male | 3,890 (12.6) | 0.83 (0.80–0.87)* | 1,973 (3.5) | 0.81 (0.76–0.87)* | 190 (0.3) | 0.90 (0.72–1.14) |
Age group | ||||||
<65 y (Ref.) | 803 (19.1) | 1.00 | 347 (8.3) | 1.00 | 64 (1.5) | 1.00 |
65–74 y | 943 (13.8) | 0.68 (0.61–0.75) | 1,709 (3.2) | 0.58 (0.50–0.68) | 118 (0.2) | 0.41 (0.28–0.60) |
75–84 y | 2,689 (11.3) | 0.54 (0.49–0.59) | 879 (3.7) | 0.43 (0.37–0.48) | 79 (0.3) | 0.22 (0.15–0.30) |
≥85 y | 5,570 (10.5) | 0.50 (0.46–0.54)* | 342 (5.0) | 0.37 (0.33–0.42)* | 43 (0.6) | 0.15 (0.11–0.20)* |
Day of stay | ||||||
<365 d (Ref.) | 847 (13.2) | 1.00 | 208 (3.2) | 1.00 | 17 (0.3) | 1.00 |
365–730 y | 1,604 (13.0) | 0.98 (0.90–1.07) | 495 (4.0) | 1.25 (1.06–1.47) | 31 (10.2) | 0.95 (0.52–1.71) |
>730 d | 7,554 (10.9) | 0.81 (0.75–0.87)* | 2,574 (3.7) | 1.16 (1.00–1.33)† | 256 (0.4) | 1.40 (0.86–2.29) |
Potential for improvement—self rated | 1,616 (15.1) | 1.46 (1.38–1.55)* | 626 (5.8) | 1.74 (1.59–1.90)* | 87 (0.8) | 2.88 (2.24–3.70)* |
Potential for improvement—staff rated | 1,245 (15.0) | 1.43 (1.34–1.53)* | 483 (5.8) | 1.69 (1.53–1.87)* | 62 (0.8) | 2.44 (1.84–3.23)* |
Clinical status | ||||||
No change (stable; Ref.) | 6,559 (11.4) | 1.00 | 2,007 (3.5) | 1.00 | 159 (0.3) | 1.00 |
Deteriorated | 2,385 (11.3) | 0.99 (0.94–1.04) | 713 (3.4) | 0.97 (0.89–1.05) | 63 (0.3) | 1.08 (0.80–1.44) |
Improved | 477 (22.3) | 2.23 (2.01–2.48)* | 237 (11.1) | 3.45 (3.00–3.98)* | 63 (3.0) | 10.96 (8.16–14.72)* |
Experiencing acute episode | 767 (13.9) | 1.28 (1.18–1.39)* | 241 (4.4) | 1.12 (1.05–1.37)* | 22 (0.4) | 1.17 (0.76–1.80) |
Conditions | ||||||
Multiple sclerosis | 319 (20.2) | 2.00 (1.76–2.26)* | 140 (8.9) | 2.57 (2.16–3.07)* | 21 (1.3) | 4.10 (2.62–6.39)* |
Parkinson's disease | 592 (15.4) | 1.45 (1.32–1.58)* | 183 (4.8) | 1.30 (1.12–1.52)* | 12 (0.3) | 0.89 (0.50–1.58) |
Pneumonia | 159 (15.1) | 1.40 (1.18–1.66)* | 47 (4.5) | 1.21 (0.90–1.63) | 5 (0.5) | 1.39 (0.57–3.36) |
Stroke | 2,027 (14.6) | 1.42 (1.34–1.49)* | 595 (4.3) | 1.19 (1.09–1.30)* | 38 (0.3) | 0.76 (0.54–1.07) |
Any fracture | 1,480 (14.4) | 1.36 (1.28–1.44)* | 525 (5.1) | 1.46 (1.33–1.61)* | 68 (0.7) | 2.18 (1.66–2.86)* |
Hip fracture | 1,130 (14.1) | 1.31 (1.23–1.40)* | 398 (5.0) | 1.40 (1.26–1.56)* | 48 (0.6) | 1.87 (1.38–2.55)* |
Osteoporosis | 1,763 (12.0) | 1.08 (1.02–1.43)* | 583 (4.0) | 1.08 (0.99–1.18) | 47 (0.3) | 0.90 (0.66–1.23) |
Arthritis | 3,120 (11.5) | 1.02 (0.98–1.07) | 1,041 (3.8) | 1.04 (0.96–1.12) | 91 (0.3) | 0.94 (0.74–1.21) |
Huntington's chorea | 12 (6.6) | 0.55 (0.30–0.98)† | 1 (0.6) | 0.14 (0.02–1.01)† | 1 (0.6) | 1.59 (0.22–11.35) |
ADL Hierarchy scale score | ||||||
0 (no impairment; Ref.) | 505 (9.0) | 1.00 | 203 (3.6) | 1.00 | 37 (0.7) | 1.00 |
1–2 (mild impairment) | 171 (9.8) | 1.09 (0.99–1.21) | 655 (3.7) | 1.03 (0.88–1.21) | 96 (0.6) | 0.83 (0.57–1.21) |
3–4 (moderate impairment) | 4,211 (13.2) | 1.53 (1.39–1.69) | 1,470 (4.6) | 0.79 (0.68–0.92) | 106 (0.3) | 0.30 (0.20–0.45) |
5–6 (severe impairment) | 3,572 (10.9) | 1.23 (1.11–1.35)* | 949 (2.9) | 1.28 (1.10–1.49)* | 65 (0.2) | 0.50 (0.34–0.73)* |
CPS score | ||||||
0 (no impairment; Ref.) | 1,387 (16.7) | 1.00 | 606 (7.3) | 1.00 | 101 (1.2) | 1.00 |
1–2 (mild impairment) | 2,853 (13.0) | 0.75 (0.70–0.80) | 1,037 (4.7) | 0.63 (0.57–0.70) | 107 (0.5) | 0.40 (0.30–0.52) |
3–4 (moderate impairment) | 3,372 (10.5) | 0.59 (0.55–0.63) | 1,031 (3.2) | 0.42 (0.38–0.47) | 66 (0.2) | 0.17 (0.12–0.23) |
5–6 (severe impairment) | 2,393 (9.4) | 0.52 (0.48–0.56)* | 603 (2.4) | 0.31 (0.27–0.35)* | 30 (0.1) | 0.10 (0.06–0.14)* |
Pain score | ||||||
0 (no pain; Ref.) | 4,227 (10.5) | 1.00 | 1,291 (3.2) | 1.00 | 115 (0.3) | 1.00 |
1–2 (daily mild to moderate pain) | 5,285 (12.2) | 1.18 (1.13–1.24) | 1,824 (4.2) | 1.33 (1.23–1.43) | 175 (0.4) | 1.42 (1.12–1.79) |
3 (daily excruciating pain) | 493 (12.3) | 1.20 (1.08–1.33)* | 162 (4.1) | 1.28 (1.08–1.51)* | 14 (0.4) | 1.23 (0.71–2.15)† |
DRS score | ||||||
0 (no depression; Ref.) | 5,016 (12.4) | 1.00 | 1,703 (4.2) | 1.00 | 191 (0.5) | 1.00 |
1–2 (mild depression) | 2,784 (10.4) | 0.82 (0.78–0.87) | 909 (3.4) | 0.80 (0.74–0.87) | 70 (0.3) | 0.55 (0.42–0.73) |
3+ (evidence of depression) | 2,186 (10.7) | 0.85 (0.81–0.90)* | 656 (3.2) | 0.76 (0.69–0.83)* | 42 (0.2) | 0.44 (0.31–0.61)* |
Falls CAP | ||||||
Not triggered (Ref.) | 8,352 (11.3) | 1.00 | 2,776 (3.7) | 1.00 | 250 (0.3) | 1.00 |
Medium risk | 1,043 (12.0) | 1.07 (1.00–1.15) | 318 (3.6) | 0.97 (0.87–1.10) | 47 (0.5) | 1.60 (1.17–2.19) |
High risk | 603 (12.4) | 1.11 (1.02–1.21)* | 182 (3.7) | 1.00 (0.86–1.16) | 7 (0.1) | 0.43 (0.20–0.90)* |
Urinary incontinence CAP | ||||||
Not triggered (Ref.) | 4,242 (10.6) | 1.00 | 1,307 (3.3) | 1.00 | 153 (0.4) | 1.00 |
Facilitate improvement | 509 (11.4) | 1.08 (0.98–1.19) | 166 (3.7) | 1.14 (0.97–1.35) | 106 (0.3) | 1.46 (0.96–2.24) |
Prevent decline | 4,660 (12.9) | 1.25 (1.19–1.30)* | 1,478 (4.1) | 1.26 (1.17–1.36)* | 25 (0.6) | 0.77 (0.60–0.98) |
Province | ||||||
British Columbia (Ref.) | 5,913 (12.3) | 1.00 | 1,545 (3.2) | 1.00 | 116 (0.2) | 1.00 |
Manitoba | 725 (5.8) | 0.43 (0.40–0.47) | 233 (1.9) | 0.57 (0.49–0.65) | 5 (0.04) | 0.16 (0.07–0.40) |
Newfoundland & Labrador | 438 (27.0) | 2.63 (2.35–2.94) | 49 (3.0) | 0.94 (0.70–1.25) | 2 (0.1) | 0.51 (0.13–2.06) |
Nova Scotia | 620 (29.5) | 2.98 (2.71–3.29) | 148 (7.1) | 2.28 (1.92–2.72) | 10 (0.5) | 1.98 (1.03–3.77) |
Saskatchewan | 2,226 (9.6) | 0.76 (0.72–0.80) | 1,283 (5.5) | 1.76 (1.63–1.90) | 170 (0.7) | 3.05 (2.41–3.86) |
Yukon | 83 (24.0) | 2.25 (1.75–2.88)* | 19 (5.5) | 1.75 (1.10–2.78)* | 1 (0.7) | 1.20 (0.17–8.59)* |
*p<0.01. †p<0.05.
PT=physical therapy; OR=unadjusted odds ratio; ADL=activities of daily living; CPS=Cognitive Performance Scale; DRS=Depression Rating Scale, CAP=Clinical Assessment Protocol.